MA51222A - Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production - Google Patents

Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production

Info

Publication number
MA51222A
MA51222A MA051222A MA51222A MA51222A MA 51222 A MA51222 A MA 51222A MA 051222 A MA051222 A MA 051222A MA 51222 A MA51222 A MA 51222A MA 51222 A MA51222 A MA 51222A
Authority
MA
Morocco
Prior art keywords
pyrimidinylamino
polymorphs
production processes
solid forms
pyrazole compound
Prior art date
Application number
MA051222A
Other languages
English (en)
Inventor
Travis Remarchuk
Anantha Sudhakar
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA51222A publication Critical patent/MA51222A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
MA051222A 2017-11-21 2018-11-20 Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production MA51222A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762589276P 2017-11-21 2017-11-21

Publications (1)

Publication Number Publication Date
MA51222A true MA51222A (fr) 2020-10-07

Family

ID=66631734

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051222A MA51222A (fr) 2017-11-21 2018-11-20 Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production

Country Status (22)

Country Link
US (3) US10370361B2 (fr)
EP (1) EP3717473B1 (fr)
JP (1) JP7303821B2 (fr)
KR (1) KR20200089713A (fr)
CN (1) CN111819174A (fr)
AR (1) AR113893A1 (fr)
AU (1) AU2018372180B2 (fr)
BR (1) BR112020010215A2 (fr)
CA (1) CA3083022A1 (fr)
CL (1) CL2020001346A1 (fr)
CO (1) CO2020006206A2 (fr)
CR (1) CR20200216A (fr)
EA (1) EA202091279A1 (fr)
IL (1) IL274824A (fr)
JO (1) JOP20200128A1 (fr)
MA (1) MA51222A (fr)
MX (1) MX2020005332A (fr)
PE (1) PE20210157A1 (fr)
SG (1) SG11202004733WA (fr)
TW (1) TWI823878B (fr)
UA (1) UA126414C2 (fr)
WO (1) WO2019104086A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3083022A1 (fr) 2017-11-21 2019-05-31 Denali Therapeutics Inc. Polymorphes et formes solides d'un compose de pyrimidinylamino-pyrazole, et procedes de production
EP3727377B1 (fr) 2017-12-20 2024-01-31 Denali Therapeutics Inc. Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
WO2023174946A1 (fr) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode précoce et non invasive d'évaluation du risque de maladie de parkinson chez un sujet

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
CA2797947C (fr) 2010-06-04 2019-07-09 Charles Baker-Glenn Derives d'aminopyrimidine au titre de modulateurs de lrrk2
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
HUE046617T2 (hu) * 2010-11-10 2020-03-30 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
BR112014011850B1 (pt) 2011-11-29 2022-01-11 Genentech, Inc Derivados de aminopirimidina, seus usos, e composição farmacêutica
EP3121173A1 (fr) 2011-11-29 2017-01-25 F. Hoffmann-La Roche AG Dérivés d'aminopyrimidine comme modulateurs lrrk2
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CA2850705C (fr) 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Derives 2-(phenyl ou pyrid-3-yl)aminopyrimidines en tant que modulateurs de la kinase lrrk2 pour le traitement de la maladie de parkinson
MX363118B (es) * 2012-05-03 2019-03-11 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2013164323A1 (fr) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Dérivés de pyrazole aminopyrimidine en tant que modulateurs de lrrk2 destinés à être utilisés dans le traitement de la maladie de parkinson
KR20230107407A (ko) 2016-06-16 2023-07-14 데날리 테라퓨틱스 인크. 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서피리미딘-2-일아미노-1h-피라졸
CA3083022A1 (fr) 2017-11-21 2019-05-31 Denali Therapeutics Inc. Polymorphes et formes solides d'un compose de pyrimidinylamino-pyrazole, et procedes de production

Also Published As

Publication number Publication date
SG11202004733WA (en) 2020-06-29
UA126414C2 (uk) 2022-09-28
MX2020005332A (es) 2021-01-08
EP3717473B1 (fr) 2024-01-10
IL274824A (en) 2020-07-30
AU2018372180A1 (en) 2020-06-18
EP3717473A1 (fr) 2020-10-07
JOP20200128A1 (ar) 2020-05-21
US10370361B2 (en) 2019-08-06
WO2019104086A1 (fr) 2019-05-31
CL2020001346A1 (es) 2020-11-20
US20210087176A1 (en) 2021-03-25
CN111819174A (zh) 2020-10-23
AU2018372180B2 (en) 2023-08-17
KR20200089713A (ko) 2020-07-27
EP3717473A4 (fr) 2021-07-07
CO2020006206A2 (es) 2020-08-10
CA3083022A1 (fr) 2019-05-31
US10851088B2 (en) 2020-12-01
US11427571B2 (en) 2022-08-30
JP2021504450A (ja) 2021-02-15
PE20210157A1 (es) 2021-01-26
JP7303821B2 (ja) 2023-07-05
BR112020010215A2 (pt) 2020-11-03
AR113893A1 (es) 2020-06-24
TW201925190A (zh) 2019-07-01
CR20200216A (es) 2021-03-19
TWI823878B (zh) 2023-12-01
US20190194170A1 (en) 2019-06-27
US20190315723A1 (en) 2019-10-17
EA202091279A1 (ru) 2020-08-19

Similar Documents

Publication Publication Date Title
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
MA41514A (fr) Procédés intégrés de synthèse chimique
MA41200B1 (fr) Procédé pour la préparation d'un composé diarylthiohydantoïne
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
MA41203A (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
MA51222A (fr) Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production
DK3390354T3 (da) Fremgangsmåde til tilvejebringelse af carbondioxid til syntese af urea
DK3568403T3 (da) Kemiske forbindelser til belægning af nanostrukturer
MA50647A (fr) Procédé de régulation d'un puits
MA50169A (fr) Procédé de production d'un électrocatalyseur
EP3341364C0 (fr) Procédé pour la préparation d'un composé à double effet inhibiteur de la néprilysine-récepteur de l'angiotensine
MA45588A (fr) Formes solides d'un stimulateur de la gcs
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
HRP20202039T8 (hr) Postupci za kemijsku sintezu supstituiranih 10h-fenotiazin-3,7-diaminskih spojeva
WO2015124764A8 (fr) Procédé de synthèse de dabigatran étexilate mésylate, intermédiaires de ce procédé et nouveau polymorphe de dabigatran étexilate
MA42423A (fr) Procédé de préparation d'un revêtement
IL268456B (en) A new process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
GB201809018D0 (en) Identification of chemical structures
MA44680A (fr) Compositions et procédés pour la production de composés
DK3495339T3 (da) Fremgangsmåde til fremstilling af reaktionsprodukt
FR3020136B1 (fr) Installation de surveillance d'un ouvrage
DK3515454T3 (da) Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan
IT201700102990A1 (it) Metodo per l’ottenimento di un target solido per la produzione di radiofarmaci
IT201700059261A1 (it) Piatto compostabile e procedimento per la produzione di un piatto compostabile.
MA41599A (fr) Formes cristallines d'un composé pyrrolopyridine